Minimize Menorrhagia in Women With Von Willebrand Disease
Status:
Recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing
recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize
menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III
multicenter prospective, randomized, crossover arm trial is to compare recombinant von
Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in
women with von Willebrand disease.
Phase:
Phase 3
Details
Lead Sponsor:
Margaret Ragni University of Pittsburgh
Collaborators:
Carnegie Mellon University Duke University University of North Carolina